Use of multivariate analysis to suggest a new molecular classification of colorectal cancer
Open Access
- 20 November 2012
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 229 (3) , 441-448
Abstract
Molecular classification of colorectal cancer (CRC) is currently based on microsatellite instability (MSI), KRAS or BRAF mutation and, occasionally, chromosomal instability (CIN). Whilst useful, these categories may not fully represent the underlying molecular subgroups. We screened 906 stage II/III CRCs from the VICTOR clinical trial for somatic mutations. Multivariate analyses (logistic regression, clustering, Bayesian networks) identified the primary molecular associations. Positive associations occurred between: CIN and TP53 mutation; MSI and BRAF mutation; and KRAS and PIK3CA mutations. Negative associations occurred between: MSI and CIN; MSI and NRAS mutation; and KRAS mutation, and each of NRAS, TP53 and BRAF mutations. Some complex relationships were elucidated: KRAS and TP53 mutations had both a direct negative association and a weaker, confounding, positive association via TP53–CIN–MSI–BRAF–KRAS. Our results suggested a new molecular classification of CRCs: (1) MSI+ and/or BRAF‐mutant; (2) CIN+ and/or TP53– mutant, with wild‐type KRAS and PIK3CA; (3) KRAS‐ and/or PIK3CA‐mutant, CIN+, TP53‐wild‐type; (4) KRAS– and/or PIK3CA‐mutant, CIN–, TP53‐wild‐type; (5) NRAS‐mutant; (6) no mutations; (7) others. As expected, group 1 cancers were mostly proximal and poorly differentiated, usually occurring in women. Unexpectedly, two different types of CIN+ CRC were found: group 2 cancers were usually distal and occurred in men, whereas group 3 showed neither of these associations but were of higher stage. CIN+ cancers have conventionally been associated with all three of these variables, because they have been tested en masse. Our classification also showed potentially improved prognostic capabilities, with group 3, and possibly group 1, independently predicting disease‐free survival. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.Keywords
This publication has 31 references indexed in Scilit:
- Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancerGenes, Chromosomes and Cancer, 2011
- Phase III Randomized Trial Assessing Rofecoxib in the Adjuvant Setting of Colorectal Cancer: Final Results of the VICTOR TrialJournal of Clinical Oncology, 2010
- Integrative approach for prioritizing cancer genes in sporadic colon cancerGenes, Chromosomes and Cancer, 2009
- Promoter hypermethylation leads to decreased APC mRNA expression in familial polyposis and sporadic colorectal tumours, but does not substitute for truncating mutationsExperimental and Molecular Pathology, 2008
- The Genomic Landscapes of Human Breast and Colorectal CancersScience, 2007
- Classification of colorectal cancer based on correlation of clinical, morphological and molecular featuresHistopathology, 2006
- Poor Survival Associated with the BRAF V600E Mutation in Microsatellite-Stable Colon CancersCancer Research, 2005
- Near-diploid and near-triploid human sporadic colorectal adenocarcinomas differ for KRAS2 and TP53 mutational statusGenes, Chromosomes and Cancer, 2003
- Mutations in APC, Kirsten-ras, and p53—alternative genetic pathways to colorectal cancerProceedings of the National Academy of Sciences, 2002
- CpG island methylator phenotype in colorectal cancerProceedings of the National Academy of Sciences, 1999